Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Cyclacel Pharmaceuticals Inc    

CYCLACEL PHARMACEUTICALS INC
Mes dernières consult.
Most popular
  Report  
 SummaryNewsCalendarCompanyFinancialsConsensusRevisions 
OFFRE ETE Zonebourse : Jusqu'à 6 mois offerts sur tous les portefeuilles
Financials (USD)
Sales 2018 -
EBIT 2018 -7,50 M
Net income 2018 -5,36 M
Debt 2018 -
Yield 2018 -
Sales 2019 -
EBIT 2019 -6,47 M
Net income 2019 -4,78 M
Debt 2019 -
Yield 2019 -
P/E ratio 2018 -
P/E ratio 2019
Capi. / Sales2018 0
Capi. / Sales2019 0
Capitalization 18,1 M
More Financials
Company
Cyclacel Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company.It uses cell cycle, transcriptional regulation and DNA damage response biology to develop innovative, targeted medicines for cancer and other proliferative diseases.The company builds a diversified biopharmaceutical... 
More about the company
Latest news on CYCLACEL PHARMACEUTICALS I
06/04CYCLACEL PHARMACEUTICALS, INC. : Other Events (form 8-K)
AQ
06/01CYCLACEL PHARMACEUTICALS, INC. : Submission of Matters to a Vote of Security Hol..
AQ
05/18CYCLACEL PHARMACEUTICALS : Reports First Quarter 2018 Financial Results
AQ
05/14CYCLACEL PHARMACEUTICALS : Management's Discussion and Analysis of Financial Con..
AQ
05/14CYCLACEL PHARMACEUTICALS, INC. : Results of Operations and Financial Condition, ..
AQ
05/14Cyclacel Pharmaceuticals Reports First Quarter 2018 Financial Results
GL
05/14CYCLACEL PHARMACEUTICALS INC : Cyclacel Pharmaceuticals, Inc. to Host Earnings C..
AC
05/14CYCLACEL PHARMACEUTICALS : to Release First Quarter 2018 Financial Results
AQ
05/08Cyclacel Pharmaceuticals to Release First Quarter 2018 Financial Results
GL
04/20CYCLACEL PHARMACEUTICALS : CYC065 CDK Inhibitor Demonstrates Synergy with Veneto..
AQ
More news
Sector news : Bio Therapeutic Drugs
06/20GILEAD SCIENCES : GSK takes billion-dollar drug fight with Gilead to top AIDS me..
RE
06/20Roche to Buy Rest of Cancer Firm -- WSJ
DJ
06/20Latecomer Sanofi looks to catch next wave of cancer therapies
RE
06/19Alexion Uses FDA Priority-Review Voucher for Blood Disorder
DJ
06/19Roche to Pay $2.4 Billion for Full Control of Foundation Medicine -- 2nd Upda..
DJ
More sector news : Bio Therapeutic Drugs
News from SeekingAlpha
2016Midday Gainers / Losers 
2016Midday Gainers / Losers 
2016Cyclacel's lead product candidates show encouraging results in early-stage st.. 
2016HEALTHCARE - TOP 5 GAINERS / LOSERS : 00 am 
2016Some Ideas For The Next Celator 
Income Statement Evolution
Consensus
 
Mean consensus OUTPERFORM
Number of Analysts 1
Average target price 7,00 $
Spread / Average Target 364%
EPS Revisions
Managers
NameTitle
Spiro Rombotis President, Chief Executive Officer & Director
David C. U'Prichard Chairman
Paul McBarron COO, CFO, Secretary, Director & Executive VP
David Glover Chief Scientist
John Michael Middlecott Banham Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
CYCLACEL PHARMACEUTICALS INC18
GILEAD SCIENCES-0.80%92 410
VERTEX PHARMACEUTICALS3.10%40 566
REGENERON PHARMACEUTICALS-11.70%35 172
GENMAB-3.97%9 557
SAREPTA THERAPEUTICS INC152.21%9 196